The ongoing Humanigen Phase III trial is double-blinded and placebo controlled. It is near conclusion. The case controlled study just published used patients that were enrolled based on EINDs and then the study authors went out and found a control group to add weight to the study. Humanigen's Phase III is enrolling 300 patients at 16 trial sites using standard methodology.